One could argue that CMS is restricting coverage of a particular instance of an accelerated approval and a set of potential approvals for a narrowly defined sub-class of beta amyloid-directed monoclonal antibodies. And this particular decision has no universal implications outside of this sub-class.
Subscribe to:
Post Comments (Atom)
< + > A Demo of Truven Health Insights Turning Data Into Actionable Insights
Renee Wiczorek, Lead Product Manager at Truven by Merative , wants healthcare institutions to ask the deep questions about the trends they’...
No comments:
Post a Comment